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method is speciﬁc to the microvasculature, and it has been validated
in animal studies and investigated further in human studies.
Comprehensive calculation of IMR requires correction for venous
pressure and collateral epicardial ﬂow. This is not done routinely,
primarily due to the time required and risk of adverse events. Theo-
retically, when the collateral ﬂow and venous pressures are both low,
the discrepancy between simpliﬁed (IMRs) and comprehensive (IMRc)
IMR calculations is small. However, it is not known whether the IMRs
method is a good approximation for IMRc in HTx recipients. The
objective of the present study was to assess (1) the agreement between
the two methods at both 7–11 weeks and 1 year post-HTx, and (2) the
changes in IMR from 7–11 weeks to 1 year post-HTx using the two
approaches.
METHODS In total, 48 patients were randomized in the study. All
patients underwent left- and right-heart catheterization with coro-
nary physiological evaluations at 7–11 weeks and 1 year after HTx.
IMRs was calculated as the product of hyperemic mean transit time
and distal coronary pressure while additionally including coronary
wedge pressure and right atrial pressure in calculation of IMRc. The
agreement between the values of IMR at the two time points using the
IMRs and IMRc methods and change was assessed using Bland-Altman
analysis and estimated from a linear mixed model.
RESULTS Mean IMRs declined signiﬁcantly over time, from
18.7 mmHg$s (95% CI¼16.2–21.1 mmHg$s) at 7–11 weeks to
15.9 mmHg$s (95% CI¼13.4–18.3 mmHg$s) at 1 year (p¼0.03), while the
decline in the mean IMRc from 16.9 mmHg$s (95% CI¼14.5–
19.2 mmHg$s) to 15.0 mmHg$s (95% CI¼12.7–17.3 mmHg$s) was not
statistically signiﬁcant (p¼0.13). Bias between the IMRs and IMRc
calculations was estimated to be 1.3 mmHg$s (p<0.01). The 95% limits
of agreement –1.2 to þ3.8 mmHg$s. The average difference between
the IMRs and IMRc calculations was signiﬁcantly different from zero
at 7–11 weeks (p¼0.04) but not at 1 year (p¼0.24) post-HTx.Time after Htx
*p7-11 weeks 1 yearIMRs mmHg$s 18.7 (16.2-21.1) 15.9 (13.4-18.3) 0.03IMRc mmHg$s 16.9 (14.5-19.2) 15.0 (12.7-17.3) 0.13*p 0.04 0.24CONCLUSIONS The IMRs method resulted in slightly higher IMR es-
timates than the IMRc method, and exhibited a somewhat greater
change over the 10-month follow-up period. However, the difference
(bias) between the methods was only 1.3 mmHg$s and is unlikely to be
of clinical importance. Therefore, it can be concluded that IMRs can be
used as an approximation for IMRc.
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BACKGROUND Fractional ﬂow reserve (FFR) is useful in deﬁning the
physiological signiﬁcance of intermediate stenosis, and requires
measurement of pressure proximal to and distal to the stenosis in
conditions of maximal hyperemia. This is induced by intracoronary or
intravenous (IV) adenosine. Regadenoson, which has an improved
safety proﬁle compared to adenosine, is approved for use in phar-
macologic myocardial perfusion imaging. This meta-analysis aims to
evaluate the efﬁcacy and safety of regadenoson, in comparison with
adenosine, for assessing FFR.
METHODS A systematic literature search of 210 potentially relevant
citations from PubMed, EMBASE, Web of Science and the CochraneCentral Register of Controlled Trials yielded 4 eligible studies con-
taining comparison data on regadenoson and adenosine.
RESULTS Four studies were included in the analysis, with a total of
202 patients undergoing elective coronary angiography. The mean
correlation coefﬁcient between FFR values induced by IV adenosine
and IV regadenoson was 0.97  0.03. The overall mean FFR of IV
adenosine and IV regadenoson were both similar at 0.80  0.04. Time
to FFR nadir was shorter for regadenoson compared to adenosine with
43.2  13.7 and 78.2  13.7 seconds (p¼0.01), respectively. Regade-
noson, compared to adenosine, had numerically lower rate of ﬂushing
(8.2% vs 18.8%), nausea (1.2% vs 8.1%), headache (5.9% vs 8.2%), and
transient heart block (0.5% vs 4.3%).
Table. Adverse Events After Adenosine and RegadenosonAdenosine (%) Regadenoson (%)Flushing 16/85 (18.8) 7/85 (8.2)Nausea 6/85 (7.1) 1/85 (1.2)Headache 7/85 (8.2) 5/85 (5.9)Transient heart block 9/205 (4.3) 1/205 (0.5)Shortness of breath 4/105 (3.8) 3/105 (2.9)Chest pain 0/80 (0) 0/80 (0)Chest discomfort 8/25 (32.0) 5/25 (20.0)Dizziness 3/60 (5.0) 1/60 (1.7)CONCLUSIONS Our composite data suggest that regadenoson pro-
duces similar pressure-derived FFR compared to adenosine, achieves
a more rapid hyperemia, and has a favorable side-effect proﬁle.
CATEGORIES IMAGING: FFR and Physiologic Lesion Assessment
KEYWORDS Adenosine, Fractional ﬂow reserve, Perfusion assess-
ment
TCT-293
Intracoronary Adenosine: Dose-Response Relationship with Hyperemia
Julien Adjedj,1 Gabor G. Toth,2 Nils P. Johnson,3 Mariano Pellicano,1
Angela Ferrara,4 Vincent Floré,1 Giuseppe Di-Gioia,5
Emanuele Barbato,5 Olivier Muller,6 Bernard De Bruyne7
1OLV cardiovascular center Aalst, Aalst, Belgium; 2Cardiovascular
Centre Aalst, AALST, Belgium; 3University of Texas Medical School,
Houston, United States; 4University of Verona, Verona, Italy;
5Cardiovascular Center Aalst, Aalst, Belgium; 6University Hospital,
Lausanne, Vaud; 7Cardiovascular Center Aalst, Belgium, Aalst, Belgium
BACKGROUND Despite the widespread adoption of intracoronary (IC)
adenosine in clinical practice, no wide-ranging, dose-response study
